Study on Doravirine and Raltegravir for Maintaining Viral Control in HIV Patients with Low Viral Load

1 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of HIV Disease, specifically in patients who have a very low level of the virus in their blood due to their current treatment. The study will use a combination of two medications: Doravirine and Raltegravir. Doravirine is also known by its code name MK-1439, and Raltegravir is known as MK-0518. These medications are taken as film-coated tablets by mouth.

The purpose of the study is to evaluate how well the combination of Doravirine and Raltegravir can maintain the suppression of the virus in patients who are already successfully managing their HIV with other treatments. Participants will be monitored over a period of time to see if the virus remains suppressed. The study will also look at the health of the immune system by measuring certain types of cells in the blood, and it will assess the quality of life of the participants through questionnaires.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study will also track any changes in the virus and any potential side effects of the medications. This research aims to provide more information on the effectiveness of this dual therapy in maintaining viral suppression in people living with HIV.

1 initial visit

Upon joining the study, the first step involves an initial visit. During this visit, eligibility is confirmed based on specific criteria such as age, HIV-1 infection status, and current treatment regimen.

A signed informed consent form is required to participate. This form ensures understanding of the study and agreement to participate.

2 treatment initiation

Participants begin the study treatment with a combination of two medications: doravirine and raltegravir. These are taken as film-coated tablets.

Doravirine is administered as a 100 mg tablet, and raltegravir is administered as a 600 mg tablet. Both medications are taken orally once daily.

3 regular follow-up visits

Regular follow-up visits are scheduled to monitor health and the effectiveness of the treatment. These visits occur at specific intervals: day 0 (D0), week 24 (W24), week 48 (W48), week 72 (W72), and week 96 (W96).

During these visits, various assessments are conducted, including blood tests to measure viral load and immune cell counts, as well as questionnaires to evaluate quality of life and treatment adherence.

4 end of treatment evaluation

At the end of the study period, an evaluation is conducted to assess the overall effectiveness of the treatment in maintaining viral suppression.

The primary goal is to determine the proportion of participants who maintain a viral load below 50 copies/mL by week 48.

Who Can Join the Study?

  • Must be at least 18 years old.
  • Must have a documented infection with HIV-1.
  • Must have a CD4 count of at least 200 cells per cubic millimeter.
    (CD4 cells are a type of white blood cell that fights infection.)
  • Must be on a stable ART regimen with at least 2 drugs for at least 6 months.
    (ART stands for antiretroviral therapy, which is the treatment for HIV.)
  • Must have an HIV-RNA plasma viral load of 50 copies/mL or less during the last 18 months.
    (Viral load is the amount of HIV virus in the blood.)
  • Must not have taken doravirine before.
    (Doravirine is a medication used to treat HIV.)
  • Must not have resistance to doravirine or raltegravir.
    (Resistance means the virus is not affected by the medication.)
  • Must sign an informed consent form.
    (This means you agree to participate in the study and understand what it involves.)
  • Must be affiliated with a social insurance program.
    (This is a requirement for patients in certain regions.)

Who Cannot Join the Study?

  • Patients who are not currently diagnosed with HIV Disease.
  • Patients who are not already on a stable HIV treatment and have their virus under control.
  • Patients who are under 18 years old or over 65 years old.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of allergic reactions to the study medications.
  • Patients who have other serious health conditions that might interfere with the study.
  • Patients who are participating in another clinical trial.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Bellvitge University Hospital L'hospitalet De Llobregat Spain

Other Sites

Site Name City Country Status
Ospedale San Raffaele S.r.l. Milan Italy
National Institute For Infectious Diseases Lazzaro Spallanzani Rome Italy
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Barcelona Spain
Centre De Recherches Et D’Etudes Sur La Pathologie Tropicale Et Le Sida Paris France
Hxsgvups Dx Lh Sbzqd Chjt I Shqm Phq Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
01.10.2020
Italy Italy
Not yet recruiting
01.10.2020
Spain Spain
Not yet recruiting
01.10.2020

Trial locations

Investigated drugs:

Doravirine is a medication used to help control HIV infection. It works by blocking a specific protein that the virus needs to multiply. By doing this, doravirine helps to lower the amount of HIV in the body, which can improve the immune system and reduce the chance of developing HIV-related illnesses.

Raltegravir is another medication used in the treatment of HIV. It works by interfering with an enzyme that the virus uses to insert its genetic material into human cells. This action helps to prevent the virus from multiplying and spreading, which can help maintain a low level of the virus in the body and support the immune system.

HIV Disease – HIV Disease is caused by the human immunodeficiency virus, which attacks the body’s immune system, specifically the CD4 cells (T cells). Over time, HIV can destroy so many of these cells that the body can’t fight off infections and disease. The progression of HIV varies among individuals and can be divided into three stages: acute HIV infection, clinical latency, and acquired immunodeficiency syndrome (AIDS). During the acute phase, individuals may experience flu-like symptoms as the virus rapidly multiplies. In the clinical latency stage, the virus is still active but reproduces at very low levels, and individuals may not have symptoms. If untreated, HIV can progress to AIDS, where the immune system is severely damaged, leading to increased vulnerability to opportunistic infections.

Trial ID:
2024-513941-35-00
Protocol code:
CREPATS 10
NCT ID:
NCT04513626
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

    Recruiting

    4 1 1
    France Spain
  • A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

    Recruiting

    2 1 1 1
    Belgium France Germany Italy Poland Portugal +1